BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26917488)

  • 21. Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
    Schrader A; Crispatzu G; Oberbeck S; Mayer P; Pützer S; von Jan J; Vasyutina E; Warner K; Weit N; Pflug N; Braun T; Andersson EI; Yadav B; Riabinska A; Maurer B; Ventura Ferreira MS; Beier F; Altmüller J; Lanasa M; Herling CD; Haferlach T; Stilgenbauer S; Hopfinger G; Peifer M; Brümmendorf TH; Nürnberg P; Elenitoba-Johnson KSJ; Zha S; Hallek M; Moriggl R; Reinhardt HC; Stern MH; Mustjoki S; Newrzela S; Frommolt P; Herling M
    Nat Commun; 2018 Feb; 9(1):697. PubMed ID: 29449575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T cell prolymphocytic leukemia with new chromosome rearrangements.
    Zver S; Kokalj Vokac N; Zagradisnik B; Erjavec A; Zagorac A; Zupan IP; Cernelc P
    Acta Haematol; 2004; 111(3):168-70. PubMed ID: 15034240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
    Hasanali ZS; Saroya BS; Stuart A; Shimko S; Evans J; Vinod Shah M; Sharma K; Leshchenko VV; Parekh S; Loughran TP; Epner EM
    Sci Transl Med; 2015 Jun; 7(293):293ra102. PubMed ID: 26109102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11q32).
    Dürig J; Bug S; Klein-Hitpass L; Boes T; Jöns T; Martin-Subero JI; Harder L; Baudis M; Dührsen U; Siebert R
    Leukemia; 2007 Oct; 21(10):2153-63. PubMed ID: 17713554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia.
    Mikhaylenko N; Wahnschaffe L; Herling M; Roeder I; Seifert M
    PLoS One; 2022; 17(9):e0274463. PubMed ID: 36129940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire.
    Garand R; Goasguen J; Brizard A; Buisine J; Charpentier A; Claisse JF; Duchayne E; Lagrange M; Segonds C; Troussard X; Flandrin G
    Br J Haematol; 1998 Nov; 103(2):488-94. PubMed ID: 9827924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients.
    Yokohama A; Saitoh A; Nakahashi H; Mitsui T; Koiso H; Kim Y; Uchiumi H; Saitoh T; Handa H; Jimbo T; Murayama K; Sakura T; Murakami H; Karasawa M; Nojima Y; Tsukamoto N
    Int J Hematol; 2012 Jan; 95(1):77-85. PubMed ID: 22189846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
    Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK3 in clear cell renal cell carcinoma: mutational screening and clinical implications.
    de Martino M; Gigante M; Cormio L; Prattichizzo C; Cavalcanti E; Gigante M; Ariano V; Netti GS; Montemurno E; Mancini V; Battaglia M; Gesualdo L; Carrieri G; Ranieri E
    Urol Oncol; 2013 Aug; 31(6):930-7. PubMed ID: 21868263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell prolymphocytic leukemia.
    de Oliveira FM; Tone LG; Simões BP; Rego EM; Marinato AF; Jácomo RH; Falcão RP
    Int J Lab Hematol; 2009 Aug; 31(4):453-6. PubMed ID: 18294235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorescent BAT-25 and BAT-26 analysis of T cell prolymphocytic leukaemia.
    Bradshaw PS; Hamoudi R; Min T; Catovsky D; Houlston RS; Yuille MR
    Leukemia; 1999 Dec; 13(12):2104-6. PubMed ID: 10602436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
    Herbaux C; Kornauth C; Poulain S; Chong SJF; Collins MC; Valentin R; Hackett L; Tournilhac O; Lemonnier F; Dupuis J; Daniel A; Tomowiak C; Laribi K; Renaud L; Roos-Weil D; Rossi C; Van Den Neste E; Leyronnas C; Merabet F; Malfuson JV; Tiab M; Ysebaert L; Ng S; Morschhauser F; Staber PB; Davids MS
    Blood; 2021 Jun; 137(25):3495-3506. PubMed ID: 33598678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
    Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
    Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.
    Bellanger D; Jacquemin V; Chopin M; Pierron G; Bernard OA; Ghysdael J; Stern MH
    Leukemia; 2014 Feb; 28(2):417-9. PubMed ID: 24048415
    [No Abstract]   [Full Text] [Related]  

  • 35. T-cell prolymphocytic leukemia is associated with deregulation of oncogenic microRNAs on transcriptional and epigenetic level.
    Patil P; Hillebrecht S; Chteinberg E; López C; Toprak UH; Seufert J; Bernhart SH; Kretzmer H; Bergmann AK; Bens S; Högel J; Müller A; Jebaraj BM; Schrader A; Johansson P; Costa D; Schlesner M; Dürig J; Herling M; Campo E; Stilgenbauer S; Wiehle L; Siebert R
    Genes Chromosomes Cancer; 2022 Jul; 61(7):432-436. PubMed ID: 35218115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
    Hu Z; Li S; Medeiros LJ; Sun T
    Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational spectrum of adult T-ALL.
    Neumann M; Vosberg S; Schlee C; Heesch S; Schwartz S; Gökbuget N; Hoelzer D; Graf A; Krebs S; Bartram I; Blum H; Brüggemann M; Hecht J; Bohlander SK; Greif PA; Baldus CD
    Oncotarget; 2015 Feb; 6(5):2754-66. PubMed ID: 25595890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: is this T-cell chronic lymphocytic leukemia?
    Soma L; Cornfield DB; Prager D; Nowell P; Bagg A
    Am J Hematol; 2002 Nov; 71(3):224-6. PubMed ID: 12410582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-cell prolymphocytic leukemia with a novel translocation (6;11)(q21;q23).
    Wong KF; Chan JK; Sin VC
    Cancer Genet Cytogenet; 1999 Jun; 111(2):149-51. PubMed ID: 10347553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.
    Badaat I; Mirza S; Padron E; Sallman D; Komrokji R; Song J; Hussaini MO
    J Clin Pathol; 2020 Apr; 73(4):209-212. PubMed ID: 31771970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.